Antibody Recognition of Cancer Cells via Glycan Surface Engineering.
Mathieu SzponarskiKarl GademannPublished in: Chembiochem : a European journal of chemical biology (2022)
Stimulation of the body's immune system toward tumor cells is now well recognized as a promising strategy in cancer therapy. Just behind cell therapy and monoclonal antibodies, small molecule-based strategies are receiving growing attention as alternatives to direct immune response against tumor cells. However, the development of small-molecule approaches to modulate the balance between stimulatory immune factors and suppressive factors in a targeted way remains a challenge. Here, we report the cell surface functionalization of LS174T cancer cells with an abiotic hapten to recruit antibodies to the cell surface. Metabolic glycoengineering followed by covalent reaction with the hapten results in antibody recognition of the target cells. Microscopy and flow cytometry studies provide compelling evidence that metabolic glycoengineering and small molecule stimulators can be combined to direct antibody recognition.
Keyphrases
- small molecule
- cell surface
- cell therapy
- cancer therapy
- flow cytometry
- immune response
- protein protein
- induced apoptosis
- drug delivery
- stem cells
- high resolution
- working memory
- dendritic cells
- mass spectrometry
- high speed
- arabidopsis thaliana
- cell death
- bone marrow
- single cell
- endoplasmic reticulum stress
- label free
- electron transfer